Business Combinations Business Combinations (Narrative) (Details) In Millions, unless otherwise specified	12 Months Ended			3 Months Ended		12 Months Ended			3 Months Ended	12 Months Ended	3 Months Ended		12 Months Ended		3 Months Ended	12 Months Ended			12 Months Ended				12 Months Ended				12 Months Ended			12 Months Ended		12 Months Ended			3 Months Ended		12 Months Ended		12 Months Ended	3 Months Ended
	Jan. 03, 2015 USD ($)	Dec. 28, 2013 USD ($)	Dec. 29, 2012 USD ($)	Jun. 28, 2014 Spinal Modulation [Member] USD ($)	Sep. 28, 2013 Spinal Modulation [Member] USD ($)	Jan. 03, 2015 Spinal Modulation [Member] USD ($)	Dec. 28, 2013 Spinal Modulation [Member] USD ($)	Jun. 07, 2013 Spinal Modulation [Member] USD ($)	Sep. 28, 2013 Spinal Modulation [Member] In Process Research and Development [Member] USD ($)	Jan. 03, 2015 Contingent Consideration Liability [Member] Fair Value, Inputs, Level 3 [Member] USD ($)	Jan. 03, 2015 Maximum [Member] Spinal Modulation [Member] USD ($)	Jun. 29, 2013 Maximum [Member] Spinal Modulation [Member] USD ($)	Jan. 03, 2015 Developed Technology Rights [Member] Spinal Modulation [Member]	Jun. 07, 2013 Developed Technology Rights [Member] Spinal Modulation [Member] USD ($)	Jan. 03, 2015 NeuroTherm, Inc. [Member] USD ($)	Jan. 03, 2015 NeuroTherm, Inc. [Member] USD ($)	Aug. 06, 2014 NeuroTherm, Inc. [Member] USD ($)	Aug. 06, 2014 NeuroTherm, Inc. [Member] Developed Technology Rights [Member] USD ($)	Jan. 03, 2015 NeuroTherm, Inc. [Member] Developed Technology Rights [Member] Minimum [Member]	Jan. 03, 2015 NeuroTherm, Inc. [Member] Developed Technology Rights [Member] Maximum [Member]	Jan. 03, 2015 NeuroTherm, Inc. [Member] Licensing Agreements [Member]	Aug. 06, 2014 NeuroTherm, Inc. [Member] Licensing Agreements [Member] USD ($)	Jan. 03, 2015 Endosense S.A. [Member] USD ($)	Jan. 03, 2015 Endosense S.A. [Member] CHF	Aug. 19, 2013 Endosense S.A. [Member] USD ($)	Aug. 19, 2013 Endosense S.A. [Member] CHF	Jan. 03, 2015 Endosense S.A. [Member] Contingent Consideration Liability [Member] Fair Value, Inputs, Level 3 [Member] USD ($)	Jan. 03, 2015 Endosense S.A. [Member] Developed Technology Rights [Member]	Aug. 19, 2013 Endosense S.A. [Member] Developed Technology Rights [Member] USD ($)	Jan. 03, 2015 Nanostim [Member] USD ($)	Oct. 11, 2013 Nanostim [Member] USD ($)	Jan. 03, 2015 Nanostim [Member] Contingent Consideration Liability [Member] Fair Value, Inputs, Level 3 [Member] USD ($)	Jan. 03, 2015 Nanostim [Member] Developed Technology Rights [Member]	Oct. 11, 2013 Nanostim [Member] Developed Technology Rights [Member] USD ($)	Sep. 28, 2013 CardioMEMS, Inc [Member] USD ($)	Mar. 30, 2013 CardioMEMS, Inc [Member] USD ($)	Jan. 03, 2015 CardioMEMS, Inc [Member] USD ($)	Feb. 27, 2013 CardioMEMS, Inc [Member] USD ($)	Jan. 03, 2015 CardioMEMS, Inc [Member] Developed Technology Rights [Member]	Jun. 28, 2014 Noncontrolling Interest [Member] Spinal Modulation [Member] USD ($)	Sep. 28, 2013 Noncontrolling Interest [Member] Spinal Modulation [Member] USD ($)
Payments to Acquire Businesses, Net of Cash Acquired	$ 147	$ 292	$ 0				$ 0									$ 147							$ 171	160						$ 121
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt																	50
Business Acquisition, Transaction Costs																	1
Other intangible assets						7		7						7				87				2							20					34
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life													12 years						11 years	12 years	5 years							7 years					10 years						11 years
Goodwill, Purchase Accounting Adjustments				(36)	(35)	(36)									(7)
Deferred income tax asset (liability), purchase accounting adjustment															7
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High																										150					65
Contingent consideration								0																	132						56
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net								124																	303						210
Payment of contingent consideration										155																	155					0
Reclassification of Acquired in Process Research and Development from indefinite-lived to definite-lived																							33														63
Equity Security Ownership Interest								19.00%																							18.00%							19.00%
Equity Security Ownership Interest And Allocated Value For Purchase Option								40																							33							60
In-Process Research and Development						45		45																							27							63
Additional Payment For Acquisition At Company Option								300																														375
Variable Interest Entity, Financial or Other Support, Amount						15	0				25	15																							9	28
Indefinite-lived Intangible Assets, Purchase Accounting Adjustments									5
Finite-Lived Intangible Assets, Purchase Accounting Adjustments					3
Business Combination, Provisional Information, Initial Accounting Incomplete Adjustment, Total Liabilities					3
Measurement period fair value adjustment to noncontrolling interest	(36)																																							(36)	(40)
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss																																				$ 29